Market Whales and Their Recent Bets on MRNA Options

Investors with a lot of money to spend have taken a bullish stance on Moderna MRNA.

And retail traders should know.

We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.

Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MRNA, it often means somebody knows something is about to happen.

So how do we know what these investors just did?

Today, Benzinga's options scanner spotted 14 uncommon options trades for Moderna.

This isn't normal.

The overall sentiment of these big-money traders is split between 57% bullish and 35%, bearish.

Out of all of the special options we uncovered, 7 are puts, for a total amount of $779,661, and 7 are calls, for a total amount of $313,943.

Projected Price Targets

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $45.0 to $200.0 for Moderna over the recent three months.

Insights into Volume & Open Interest

In terms of liquidity and interest, the mean open interest for Moderna options trades today is 740.31 with a total volume of 1,287.00.

In the following chart, we are able to follow the development of volume and open interest of call and put options for Moderna's big money trades within a strike price range of $45.0 to $200.0 over the last 30 days.

Moderna Option Volume And Open Interest Over Last 30 Days

Noteworthy Options Activity:

Symbol PUT/CALL Trade Type Sentiment Exp. Date Ask Bid Price Strike Price Total Trade Price Open Interest Volume
MRNA PUT TRADE BULLISH 06/20/25 $24.6 $22.35 $23.1 $130.00 $577.5K 35 0
MRNA CALL SWEEP BULLISH 09/20/24 $11.35 $11.25 $11.35 $140.00 $66.5K 661 0
MRNA CALL TRADE BEARISH 07/19/24 $5.7 $5.5 $5.5 $140.00 $60.5K 1.9K 36
MRNA CALL SWEEP BULLISH 01/17/25 $5.9 $5.65 $5.85 $200.00 $58.5K 2.4K 45
MRNA PUT TRADE BEARISH 06/21/24 $46.0 $42.15 $46.0 $180.00 $46.0K 10 0

About Moderna

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Following our analysis of the options activities associated with Moderna, we pivot to a closer look at the company's own performance.

Where Is Moderna Standing Right Now?

  • With a trading volume of 2,071,149, the price of MRNA is up by 0.08%, reaching $133.37.
  • Current RSI values indicate that the stock is may be oversold.
  • Next earnings report is scheduled for 42 days from now.

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Moderna with Benzinga Pro for real-time alerts.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date of Trade
▲▼
ticker
▲▼
Put/Call
▲▼
Strike Price
▲▼
DTE
▲▼
Sentiment
▲▼
Posted In: OptionsMarketsBZI-UOA
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...